- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Dental Adverse Effects of Anti-CD20 Therapies ; volume:13 ; number:3 ; day:26 ; month:4 ; year:2024 ; pages:917-930 ; date:6.2024
Neurology and Therapy ; 13, Heft 3 (26.4.2024), 917-930, 6.2024
- Creator
-
Bartak, Hélène
Fareh, Tasnim
Ben Othman, Nouha
Viard, Delphine
Cohen, Mikael
Rocher, Fanny
Ewig, Elliot
Drici, Milou-Daniel
Lebrun-Frenay, Christine
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40120-024-00616-7
- URN
-
urn:nbn:de:101:1-2408062117595.042842651795
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
10.03.2026, 3:32 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Bartak, Hélène
- Fareh, Tasnim
- Ben Othman, Nouha
- Viard, Delphine
- Cohen, Mikael
- Rocher, Fanny
- Ewig, Elliot
- Drici, Milou-Daniel
- Lebrun-Frenay, Christine
- SpringerLink (Online service)
Other Objects (12)
Anti-CD20 therapies and pregnancy in neuroimmunologic disorders: a cohort study from Germany
Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis
Pharmakokinetik des monoklonalen anti-CD20 Antikörpers Rituximab bei aggressiven CD20 positiven B-Zell-Lymphomen
Fatale neurologische Nebenwirkung einer Anti-CD20-Antikörper-Therapie
Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment
A novel glycosylated anti-CD20 monoclonal antibody from transgenic cattle
Bcl2 inhibitor venetoclax +/− Anti-CD20: what do deep remissions mean?
Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation
Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders
The dental pulp : biology, pathology, and regenerative therapies
Ein Überblick über den klinischen Gebrauch des chimären anti-CD20 Antikörpers Rituximab
Anti-angiogenic therapies in brain metastases
Anti-CD20 therapies and pregnancy in neuroimmunologic disorders: a cohort study from Germany
Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis
Pharmakokinetik des monoklonalen anti-CD20 Antikörpers Rituximab bei aggressiven CD20 positiven B-Zell-Lymphomen
Fatale neurologische Nebenwirkung einer Anti-CD20-Antikörper-Therapie
Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment
A novel glycosylated anti-CD20 monoclonal antibody from transgenic cattle
Bcl2 inhibitor venetoclax +/− Anti-CD20: what do deep remissions mean?
Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation
Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders
The dental pulp : biology, pathology, and regenerative therapies
Ein Überblick über den klinischen Gebrauch des chimären anti-CD20 Antikörpers Rituximab
Anti-angiogenic therapies in brain metastases
Anti-CD20 therapies and pregnancy in neuroimmunologic disorders: a cohort study from Germany
Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis
Pharmakokinetik des monoklonalen anti-CD20 Antikörpers Rituximab bei aggressiven CD20 positiven B-Zell-Lymphomen
Fatale neurologische Nebenwirkung einer Anti-CD20-Antikörper-Therapie
Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment
A novel glycosylated anti-CD20 monoclonal antibody from transgenic cattle
Bcl2 inhibitor venetoclax +/− Anti-CD20: what do deep remissions mean?
Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation
Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders
The dental pulp : biology, pathology, and regenerative therapies
Ein Überblick über den klinischen Gebrauch des chimären anti-CD20 Antikörpers Rituximab